The p16 gene expresses two alternative transcripts (p16a and p16b) involved in tumor suppression via the retinoblastoma (Rb) or p53 pathways. Disruption of these pathways can occur through inactivation of p16 or p53, or activating mutations of cyclin dependant kinase 4 gene (Cdk4). We searched for p16, Cdk4 and p53 gene mutations in 20 squamous cell carcinomas (SSCs), 1 actinic keratosis (AK), and 28 basal cell carcinomas (BCCs), using PCR-SSCP. A deletion and methylation analysis of p16 was also performed. Six dierent mutations (12%) were detected in exon 2 of p16 (common to p16a and p16b), in ®ve out of 21 squamous lesions (24%) (one AK and four SCCs) and one out of 28 BCCs (3.5%). These included four (66%) ultraviolet (UV)-type mutations (two tandems CC : GG to TT : AA transitions and two C : G to T : A transitions at dipyrimidic site) and two transversions. P53 mutations were present in 18 samples (37%), mostly of UV type. Of these, only two (one BCC and one AK) harboured simultaneously mutations of p16, but with no consequence on p16b transcript. Our data demonstrate for the ®rst time the presence of p16 UV induced mutations in non melanoma skin cancer, particularly in the most aggressive SCC type, and support that p16 and p53 are involved in two independent pathways in skin carcinogenesis.
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Keywords: INKA-ARF locus; p16 gene; p53 gene; Cdk4 gene; non melanoma skin cancers; tandem mutation Skin carcinomas are the most frequent tumors occurring worldwide in Caucasian people. Two main distinct subtypes of epithelial skin cancers can be distinguished, both arising from keratinocytes, at sunexposed sites. Basal cell carcinomas (BCC) grow slowly, nearly never metastasise, whereas squamous carcinomas (SCC) are more dierentiated and aggressive tumors, arising in some cases from pre-cancerous lesions such as actinic keratosis (AK) and Bowen disease (BW).
The most frequent genetic lesions observed in skin carcinomas are p53 mutations (Basset-Seguin et al., 1994) , in majority of UV type (i.e. double transition CC : GG TT : AA, or transition C : G T : A occurring at dipyrimidic sites; Brash et al., 1991) .
More recently, in BCCs, activation of the Sonic Hedgehog (Shh) pathway has been reported. This can occur through inactivating somatic mutations in the patched gene (PTCH) (Gailani et al., 1996) , or in a lesser extent, through activating mutations in smoothened (Smo) or Shh (Oro et al., 1997; Xie et al., 1998) .
Another important pathway in the control of cell proliferation is the pathway involving Rb. This pathway may be disrupted through inactivation of Ink4s (inhibitors of cyclin-dependant kinase 4) or activation of Cdk4 (via mutation or ampli®cation).
The INKA-ARF locus localized at 9p21 is one of the sites mutated most frequently in human cancer. It encodes two alternative reading frame proteins, p16INK4A (exons 1a, 2 and 3) and p14ARF (exons 1b (E1b), 2 and 3) (Stone et al., 1995) , both involved in the negative control of cell proliferation. P16INK4A is a CDK4 inhibitor that speci®cally acts at the G1/S phase of the cell cycle, by negatively controlling retinoblastoma (RB) phosphorylation status (Serrano et al., 1993) . P14ARF is a structurally dierent protein, which has been recently shown to act both at G1/S and G2/M phases, in a p53 dependent manner, via binding and inhibition of the protein MDM2, which itself promotes P53 degradation (Stott et al., 1998) .
Several arguments suggest that the INKA-ARF locus may play a role in epithelial skin cancer development. Firstly, loss of heterozygosity at chromosome 9p occurs frequently in SCC and in actinic keratosis (Quinn et al., 1994a) , as well as, less frequently, in a subset of BCC (Quinn et al., 1994b) . Secondly, inactivation of p16 (by mutation, deletion, or hypermethylation) is frequently detected in tumors of epidermoid histological type (i.e. head and neck carcinoma (Jares et al., 1997) , or esophageal cancer (Muzeau et al., 1997) . Additionally, patients carrying a mutated p16 allele may develop squamous carcinoma (Yarbrough et al., 1996; Whelan et al., 1995) , in association with the loss of the wild type allele in the tumor. Finally, mice generated through targeted disruption of exon 2 and 3 of INKA/ARF are highly tumor prone, and particularly develop squamous carcinomas after UVB irradiation . The recent knowledge of the link between the p16/Rb and p53 pathways through the alternative transcript p14arf emphasizes the importance of comparative analysis of these pathways in human skin cancer, for which no information is available at the moment. To delineate the respective role of p53, p16INKa and p14arf as tumor suppressors and Cdk4 as an oncogene in the genesis of epithelial skin cancer, we examined 49 skin tumors using detection of mutations, deletions and methylation analysis of the p16 gene, and mutation detection of p53 and Cdk4 genes.
A total of 49 selected epithelial skin neoplasms (28 basal cell carcinoma, 20 squamous cell carcinoma, and one actinic keratosis) were collected following surgical resection (Montpellier and Saint-Louis Hospitals, France). Part of these specimens was fresh frozen in liquid nitrogen and stored at 7808C. A second part was formalin-®xed and paran-embedded, and histopathological assessment was kindly performed by Drs O Verola and J Rivet, Pathology Department, SaintLouis Hospital. Tumor-DNA was prepared from tissues as previously described (MoleÁ s et al., 1993) .
Loss of heterozygosity at 9p21 locus was ®rst examined by studying polymorphism of four polymorphic markers sparing the 9p21 locus (from centromere to telomere: D9S171, D9S1752, D9S1748, and D9S1749) in 12 skin carcinomas (3 SSCs, 9 BCCs) and 12 matched-paired normal skin. No allelic loss was observed in these cases. Furthermore, a PCR-RFLP analysis was conducted in all 49 samples to examine the presence of intragenic polymorphisms in exon 2 (G/A at nucleotide 442) and exon 3 (G/C at nucleotide 500) of the p16 gene, which respectively ablate a SacII or a MspI restriction sites (Ueki et al., 1994; Chaubert et al., 1996) . A total of 21 tumors harboured either the A allele in exon 2, or the G allele in exon 3, all being heterozygous for these polymorphisms. Therefore LOH was excluded in 33 tumoral samples, 12/20 SSCs (57%) and 21/28 BCCs (75%). Yet, deletion analysis was not informative in 16 samples (7 BCCs, 8 SSCs and 1 AK), particularly in all tumors harbouring a p16 mutation. PCR-SSCP analysis was performed as previously described (Sou®r et al., 1998; MoleÁ s et al., 1993) . The coding sequence of exons 1a and 2 of the p16 gene including adjacent splice junctions was examined. Abnormal bands in exon 2 were detected in 18 out of the 49 tumors analysed (see Figure 1 ). No abnormal band was seen in exon 1a. DNA sequencing showed in 12 samples the previously described Ala148Thr polymorphism, whereas six dierent mutations in the coding sequence were found in six other samples (see Table 1 ). Four were single nucleotide substitutions, including two C : G T : A transitions at dipyrimidic sites and two transversions (an A : T T : A and a C : G G : C), and two were double substitutions CC : GG TT : AA (see Table 1 ). Two are nonsense mutations, two are mutations of the acceptorsplicing site of exon 2, and two are missense mutations (see Table 1 ). Pathogenicity of each mutation was assessed by using several criteria's, including, reference to previously published germline or somatic mutations (Pollock et al., 1996) , localization of the mutation in one of the four ankyrin repeats of the protein (Lilischkis et al., 1996) , in a conserved codon between the murine and the human cDNA , and in a codon which has been shown to be essential for the protein activity by previous functional studies . Five mutations were detected in squamous lesions (four SSCs, one AK). The two double substitutions were previously described as UV mutations in melanoma cell lines and in sporadic melanoma (Kamb et al., 1994; Pollock et al., 1995; Healy et al., 1996) .
The two splicing mutations occurred in the acceptor site of the second exon, in two SSCs. One was previously characterized in a bladder tumor , and the second in a cancer of the nasopharynx (Lo et al., 1995) . Although RNA expression experiments were not possible, it is likely that these nucleotide changes disturb the splicing of the gene, possibly resulting in RNA containing some intronic sequence.
A nonsense mutation, which has not been previously described, to our knowledge, was found in a precancerous lesion (AK 241). Arg129Ter residues at the end at the fourth ankyrin repeat, leading to a truncated protein. This suggested that p16 mutation could be an early event in SCC oncogenesis, although no mutation detected in ®ve cases of BW diseases. In line with this, loss of heterozygosity at 9p locus was present in 39% Figure 1 Examples of SSCP shifts for exon 2 of the p16 gene in primary epithelial skin tumors. Lanes 1 ± 3, tumoral shifted samples: SCC 79, AK 241, BCC 153, respectively; lanes 4 and 5, normal controls. Arrows indicate abnormal mobility shifts seen in tumoral samples. PCR-SSCP analysis of the p16 and p53 genes was performed as previously described (Sou®r et al., 1998; MoleÁ s et al., 1993) . For exon 1b, two overlapping PCR products were generated using the following primers p14F1 5'-TCAGG-GAAGGGCGGGTGCG-3', P14R1 5'-GCCGCGGGATGT-GAACCA-3', p14F2 5'-GCCGCGAGTGAGGGTTTT-3', p14R2 5'-CACCGCGGTTATCTCCTC-3'. The exons 2, 5 and 8 of Cdk4 were ampli®ed using¯anking intronic primers: (i) exon 2 CDK4F2 5'-AGCGACTTTTGGTGATAGGAGT-3', CDK4R2 5'-GGCTGTCTTTTCCCTTTTACTC-3' (PCR product: 322 bp), (ii) exon 5, CDK4F5 5'-AGAGTGATTGCCCGTAGC-3', CDK4R5 5'-GCAAGGTATGGATGTGGT-3' (PCR product: 296 bp), and (iii) exon 8, CDK4F8 5'-GCTCATCCCAGG-TATTGT-3', CDK4R8 5'-TTGCCCTCTCAGTGTCCA-3' (PCR product: 234 bp). Total PCR reactions volume was 20 ml including 50 ± 100 ng of genomic DNA template, 30 pmol of each primer, 0.5 UI of Taq polymerase (GibcoBrl) and 0.1 ml of a33P-dCTP (Amersham). Final MgC1 2 concentration 1.5 mM for all PCR reactions. PCR was processed with an annealing temperature of 608C for exon 1b, and 558C for the three studied exons of Cdk4. For SSCP, all PCR products were migrated on two 0.16 TBE/Hydrolink MDE gels (FMC Bioproducts), with 8% glycerol at room temperature (RT), and without glycerol at +48C. Gels were run at 8W, either 14 h at RT or 12 h at 48C, dried, and exposed for autoradiography of actinic keratosis in a recent study (Rehman et al., 1996) . One missense mutation of p16 (Pro114Leu) was also detected in one BCC (T 153) out of 28 (3.5%). This nucleotide change was previously found in three melanoma cell lines and in a primary astrocytoma Ueki et al., 1994) , and was absent in constitutional DNAs from 100 healthy individuals. Thus, we assessed it as a pathogenic mutation, although no matched normal DNA could be studied.
The presence of homozygous deletions at 9p21 locus encompassing E1b in numerous cell lines and tumors, in particular of epidermoid type, led us to propose that mutations of E1b could be involved in epithelial skin cancer formation, in particular in those that do not harbour p53 mutations. No sequence variants of E1b were detected in all 49 tumor samples (either in the p53 positive or negative), suggesting that mutations in E1b are not a common event during tumor progression in skin epithelial tumors.
Ten mutations of the p53 gene have been characterized from a previous study (MoleÁ s et al., 1993) . Coding sequence and¯anking intronic sequences including splicing sites from exons 4 to 9 were further examined in 20 new samples (14 BCCs, 5 SCCs and 1 AK). Ten abnormal bandshifts were detected, one in exon 5, three in exon 6, four in exon 7, and two in exon 8. Sequencing analysis showed eight dierent mutations in six BCCs, one SCC, and one AK, and a neutral polymorphism in two BCCs (see Table 2 ). These mutations include four C : G T : A transitions at dypyrimidic site (three BCCs, AK 241), one double transition CC : GG TT : AA (BCC 353), one transition A : T G : C (BCC 274), and a C : G T : A transition coupled with a one base deletion (G) (BCC 355). Six are missense mutations, one leads to a premature codon stop, and one is a frameshift mutation. Searching in p53 databases mutations (Hainaut et al., 1998; Beroud et al., 1998) concluded that one mutational event (BCC 355) has not been previously described, whereas seven were previously identi®ed, one in a sporadic melanoma, and six in skin epithelial tumors (AK 241, SCC 350, BCC 351, BCC 352, BCC 353, BCC 354). In summary, 18 pathogenic p53 mutations were present in 49 tumoral samples, 13 out of 28 (46%) BCCs, and four out of 21 (19%) SCCs and pre-SSC lesions.
For mutational analysis of the Cdk4 gene, we screened genomic sequence encompassing residues previously shown to be mutated in familial melanoma (Zuo et al., 1996; Sou®r et al., 1998) , or to aect p16 binding (i.e. domains encompassing the ®rst 58 Nterminal aminoacids or the C-terminal region of Cdk4; Coleman et al., 1997) . We therefore examined the coding sequence and adjacent splicing sites of exons 2, 5 and 8 of the gene. No SSCP variants were detected in all 49 samples, indicating that activation of this gene via mutation does not occur frequently in skin epithelial tumors.
Methylation analysis of p16 was performed as previously described (Merlo et al., 1995) . 5 mg of genomic DNA was digested with EcoRI alone or in combination with the methylation sensitive enzyme SmaI, transferred to a Hybond N + nylon membrane, and hybridized using an alpha32 dCTP random labelled PCR product of p16 exon 1 (p16F1R1) sparing the SmaI methylation sites. A complete digestion of the 4.3 kb EcoRI band by SmaI was observed (experiments were repeated twice) in 15 out of Glu88Glu Gly89Ser Pro114Leu
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The sequence is written 5'?3' for the coding strand; the uppercase letter of sequence is the base mutated; the text in bold indicates nucleotides and aminoacids changes. SCC=squamous cell carcinoma; BCC=basal cell carcinoma; AK=actinic keratosis; sa=site acceptor. Mutations in samples 79, 121, 132 and 153 are predicted to be UVB induced mutations 49 tumors (8/20 SCCs, three of which harbouring a p16 mutation; 7/28 BCC, one having a p16 mutation) (data not shown). Therefore, this indicates that p16 inactivation via promoter methylation does not seem to be a frequent event in non-melanoma skin cancers, although only 1/3 of the tumors could be analysed. This study allowed us to characterize six dierent pathogenic somatic mutations of the p16 gene, in six out of 49 tumors (12%), four SCCs, one AK and one BCC. In our panel, p16 mutations are more frequent in SCCs and pre-SSC lesions (®ve out of 21, 24%) than in BCCs (one out of 28, 3.5%) (w 2 =4.57, P=0.03). In addition, these occur in SCC lesions as frequently than p53 mutations (24% vs 18%), suggesting that the p16 gene should be examined in SCCs without p53 mutations. Several arguments from recent publications enhance the role of p16 in SCC oncogenesis. Firstly, deletions or loss of expression of p16 occur in poorly dierentiated murine squamous skin carcinomas (Linardopopoulos et al., 1995) . Secondly, growth of murine squamous epithelial cells is inhibited by wild type p16 (Enders et al., 1996) . Thirdly, tumorigenesis of squamous skin cancer mediated by ras depends on signalling pathways that act preferentially through cyclin D1 and CDK4 (Robles et al., 1998) , which are inhibited by P16INKA (Serrano et al., 1993) . The lower frequency of p16 abnormalities in BCCs could probably be explained by the fact that in this tumor, tumorigenesis preferentially occurs through abnormalities of Shh or p53 signalling pathways. Yet, loss of expression of p16INKA protein was previously reported in BCC (Chang et al., 1997) , and therefore, inactivation of p16 may be relevant in oncogenesis of some BCCs.
In our study, 66% of the mutations correspond to the UVB signature (Brash et al., 1991) . The two transversions could also correspond to the mutation spectrum of UV light although they are less frequent (Nishigori et al., 1994) . This is the ®rst indication of p16 inactivation by UV radiation in non melanoma skin cancers, although such mutations were previously reported in melanoma cell lines and sporadic melanoma (Maestro et al., 1995; Pollock et al., 1995; Healy et al., 1996) . Our results are in accordance with those of Kubo et al. (1997) , who detected 15% of p16 mutations in a set of SCCs, two of them being possibly of UV type. In addition, p16 may play a role in UVinduced cell cycle arrest, supporting data that its alteration could constitute an important step in UV induced tumorigenesis (Wang et al., 1996) .
A role for P14ARF in skin carcinogenesis could be suggested because four p16 mutations induce changes on P14ARF (see Table 1 ), and mice nullizygotous for p14arf develop papillomas and epidermoid cutaneous carcinoma at multiple sites . However, two mutations are localized in nonconserved aminoacids between human and mouse protein , and some p14arf exon 2 mutants remain fully active in mediating cell cycle arrest in mouse (Quelle et al., 1997) . Generation of mice lacking speci®cally exon 1 alpha (speci®c of P16INKA) is warranted in order to precise the respective role of both proteins in skin carcinogenesis, as mice previously generated were nullizygous for both genes .
Only two tumors displayed p16 and p53 mutations (BCC 153, AK 241 Cf. Table 3 ). The frequency of these double mutants is exactly the one expected if p16 and p53 mutations were independent events (frequency of double mutations=2/49=5% vs 4.5%=the product of individual mutations frequency for p16 and p53). This con®rms previous data (Pomerantz et al., 1998; Gruis et al., 1995) , and suggest that p16 and p53 act through dierent pathways, each being necessary in the tumorogenesis process.
No tumors had simultaneous alteration of p53 and p14arf (see Tables 1 and 3) , con®rming a previous report showing a reciprocal relationship between p14arf and p53 mutational events, as P53 and (P16INKA +P14ARF) de®cient cancers represent less than 2% of all available cases (Pomerantz et al., 1998) .
In conclusion, these data strongly support, that in addition to p53 mutation, deregulation of the CDK4/ cyclin D pathway, via p16 mutations, is of biological signi®cance in the development of epithelial skin tumor, particularly in the more aggressive SCC type. From the mutation pattern, it can be concluded that most of the carcinogenic DNA lesions were pyrimidinecytosine photoproducts caused by the UVB portion of sunlight. Furthermore, p16 and p53 mutations seem to be independent events in skin carcinogenesis. 
